Breathe Well Live Well
|
FDA OKs New Maintenance Asthma Treatment Arnuity Ellipta
Medscape Other important safety information included in the highlights section of the prescribing information includes the following: "Arnuity Ellipta is contraindicated for primary treatment of status asthmaticus or acute episodes of asthma requiring intensive … |
View full post on asthma – Google News
|
FDA approves GSK's Arnuity Ellipta to treat asthma in US
Pharmaceutical Business Review The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) fluticasone furoate inhalation powder, to be sold as Arnuity Ellipta, as a daily-once corticosteroid for treatment of asthma in patients aged above twelve years in the US. |
View full post on asthma – Google News
|
FDA approves GlaxoSmithKline's Arnuity Ellipta for treatment of asthma
News-Medical.net GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 … |
View full post on asthma – Google News
|
GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the …
MarketWatch 20, 2014 /PRNewswire/ — GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic … |
View full post on asthma – Google News
The Pharma Letter |
GSK and Theravance submit US sNDA for Breo Ellipta in asthma
The Pharma Letter Today's filing is based on data generated from the comprehensive clinical development program for FF/VI in asthma. The clinical development program comprised 48 clinical pharmacology studies in 1,328 subjects and 23 clinical studies in 12,051 patients … Glaxo, Theravance File Asthma Drug Application with FDA Glaxo submits new drug application for asthma treatment GSK and Theravance Announce Submission to US Regulatory Authorities for … |
View full post on asthma – Google News
|
Relvar Ellipta Approved in Japan for Treatment of Asthma
Benzinga GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment of bronchial asthma (in cases where … GSK, Theravance Announce Relvar Ellipta Approval In Japan For Asthma … Double asthma approval in Japan lifts SkyePharma Asthma drugs head Japan approvals |
View full post on asthma – Google News
|
GSK, Theravance Announce Relvar Ellipta Approval In Japan For Asthma …
RTT News GlaxoSmithKline plc(GSK: Quote,GSK.L), and Theravance, Inc.(THRX: Quote), Friday said that Relvar Ellipta for the treatment of bronchial asthma got approval from the Japanese Ministry of Health, Labour and Welfare. The company said Relvar Ellipta is … Japan approves lung drugs from GSK/Theravance and SkyePharma Glaxo's Relvar Lung Treatment Recommended by EU Regulator GlaxoSmithKline Treatments Given Positive Opinion In Europe, Approved in Japan |
View full post on asthma – Google News